Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, has announced its participation in three major virtual investor conferences in April 2025: H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, has announced its participation in three major virtual investor conferences in April 2025:
- H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference on April 2, 2025, featuring a fireside chat at 9:30 am ET
- 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, with a fireside chat scheduled for 8:00 am ET
- Stifel's 2025 Virtual Targeted Oncology Forum on April 9, 2025, including a fireside chat at 12:00 pm ET
All events will include fireside chats and one-on-one meetings. Live webcasts will be available on Compugen's website investor relations page, with replays accessible after the events.
Details
News Market Reaction – CGEN
The recorded move for CGEN in the trading session of this news was -2.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference
Date: Wednesday, April 2, 2025
Format: Fireside chat and 1x1 meetings
Fireside chat time: 9:30 am ET
24th Annual Needham Virtual Healthcare Conference
Date: Monday, April 7, 2025
Format: Fireside chat and 1x1 meetings
Fireside chat time: 8:00 am ET
Stifel's 2025 Virtual Targeted Oncology Forum
Date: Wednesday, April 9, 2025
Format: Fireside chat and 1x1 meetings
Fireside chat time: 12:00 pm ET
Live webcasts of the fireside chats will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. Replays will be available following the live events.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to enhance anti-cancer immunity. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-multiple-virtual-investor-conferences-in-april-2025-302411894.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.